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Objective:Hyperactivity, impulsiveness, anddistractibility are
commonproblems inchildrenwithautismspectrumdisorder
(ASD). Extended-release guanfacine is approved for children
with attention deﬁcit hyperactivity disorder but not well
studied in ASD.
Method: In a multisite, randomized clinical trial, extended-
release guanfacine was compared with placebo in children
with ASD accompanied by hyperactivity, impulsiveness, and
distractibility.
Results: Sixty-two subjects (boys, N=53; girls, N=9; mean
age=8.5 years [SD=2.25]) were randomly assigned to
guanfacine (N=30) or placebo (N=32) for 8 weeks. The
guanfacine group showed a43.6%decline in scores on the
Aberrant Behavior Checklist-hyperactivity subscale (least
squares mean from 34.2 to 19.3) compared with a 13.2%
decrease in the placebo group (least squares mean from
34.2 to 29.7; effect size=1.67). The rate of positive re-
sponse (much improved or very much improved on the
Clinical Global Impression-Improvement scale) was 50%
(15 of 30) for guanfacine compared with 9.4% (3 of 32) for
placebo. A brief cognitive battery tapping working memory
and motor planning showed no group differences before
or after 8 weeks of treatment. The modal dose of guan-
facine at week 8 was 3 mg/day (range: 1–4 mg/day), and
the modal dose was 3 mg/day (range: 2–4 mg/day) for pla-
cebo. Four guanfacine-treated subjects (13.3%) and four
placebo subjects (12.5%) exited the study before week 8.
The most common adverse events included drowsiness,
fatigue, and decreased appetite. There were no signiﬁcant
changes on ECG in either group. For subjects in the guan-
facine group, blood pressure declined in the ﬁrst 4 weeks,
with returnnearly tobaselinebyendpoint (week8). Pulse rate
showed a similar pattern but remained lower than baseline
at endpoint.
Conclusions: Extended-release guanfacine appears to be
safe and effective for reducing hyperactivity, impulsiveness,
and distractibility in children with ASD.
AJP in Advance (doi: 10.1176/appi.ajp.2015.15010055)
The pervasive developmental disorders (autistic disorder,
pervasive developmental disorder not otherwise speciﬁed,
and Asperger’s syndrome) deﬁned in DSM-IV (1) have been
subsumed under the single diagnostic category of autism
spectrum disorder (ASD) in DSM-5 (2). A recent detailed
review of epidemiological studies estimates an ASD preva-
lence of 6.2 per 1,000 childrenworldwide (3). Of these, 30%2
40% are intellectually disabled (3).
Inaddition toessential diagnostic characteristics, children
with ASD may exhibit serious behavioral problems such as
tantrums, aggression and self-injury (4), and anxiety (5), as
well as hyperactivity, impulsiveness, and distractibility (6–8).
Although DSM-IV advised against giving a diagnosis of at-
tention deﬁcit hyperactivity disorder (ADHD) to children
with ASD (1), DSM-5 discarded this convention (2). When
present, hyperactivity, impulsiveness, and distractibility add
to the overall impairment in children with ASD (9). Not
surprisingly, stimulants and alpha2 agonists are commonly
used to treat ADHD symptoms in children with ASD (10).
Few studies have rigorously tested treatments of ADHD
symptoms in children with ASD. The alpha2 agonists clo-
nidine and guanfacine have been evaluated in open and small
randomized trials among children with ASD, with in-
conclusive results on efﬁcacy and recurring problems with
sedation and irritability (11). Using a double-blind crossover
design, our research grouppreviously tested threedose levels
of immediate-release methylphenidate in 72 children with
ASD (12). All three dose levels of methylphenidate were
superior toplacebo,with score reductions of small tomedium
effect sizes on theAberrant BehaviorChecklist-hyperactivity
subscale. The overall positive response rate on the Clinical
Global Impression–Improvement (CGI-I) scale of 49% was
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lower than the 65%270% positive response rate in children
with ADHD uncomplicated by ASD (13, 14). Furthermore,
adverse effects occurred at higher than expected rates in
children with ASD compared with children with ADHD
uncomplicated by ASD (12, 14). Harfterkamp et al. (15)
reported equivocal results in an 8-week placebo-controlled
trial of atomoxetine in 97 children with ASD and ADHD
symptoms. Collectively, these results suggest that additional
pharmacological strategies are needed for childrenwithASD
and ADHD symptoms for whom stimulants are not effective
or intolerable.Wepreviously conducted anopen-label trial of
immediate-release guanfacine in 25 subjects with a recent
history of failed treatment with methylphenidate. In that
study,weobserved a 39%reduction on theAberrantBehavior
Checklist hyperactivity subscale and a 48% (12 of 25) positive
response rate on the improvement item of the CGI (16, 17).
The purpose of the present study was to test whether
extended-release guanfacine would be superior to placebo in
children with an ASD accompanied by moderate to severe
hyperactivity.
METHOD
Design
This was a ﬁve-site randomized, double-blind placebo-
controlled, ﬁxed-ﬂexible dose clinical trial conducted by
theResearchUnitsonPediatricPsychopharmacologyAutism
Network. Using permuted blocks to conceal allocation, eli-
gible subjects were randomly assigned within site without
stratiﬁcation in a 1:1 ratio to extended-release guanfacine or
placebo for 8 weeks. At week 8, subjects who met pre-
determined criteria for positive response (see below) in the
double-blind phase continued with their randomized treat-
ment (extended-release guanfacine or placebo) for 8 more
weeks without breaking the treatment mask. The treatment
blind was broken for subjects who did not show a positive
response. Subjects who were randomly assigned to placebo
and did not showa positive responsewere offered open-label
treatment with extended-release guanfacine for 8 weeks.
Subjects who showed insufﬁcient response to guanfacine in
the double-blind phase were tapered off the medication and
managed outside of the study. This report focuses on the
results of the acute double-blind phase.
Setting and Subjects
The study was approved by the institutional review board at
each site (University of California at Los Angeles, Emory
University, Massachusetts General Hospital, University of
Washington at Seattle, and Yale University) and registered
with Clinicaltrials.gov (NCT01238575). Study subjects were
recruited from clinic registries, current referrals to the active
clinical programs at each site, local website announcements,
and outreach to parent support groups. No study data were
collected until a parent (or guardian) signed the informed
consent. Protocol adherence was monitored through weekly
teleconferences with the principal investigators and
coordinators. The coordinating centers (Yale University
and Emory University) conducted semiannual site visits
and managed study data. An external data, safety, and moni-
toring board reviewed safety, enrollment, and attrition three
times a year.
An experienced multidisciplinary team at each site con-
ducted the screening, baseline, and follow-up assessments.
Tobeeligible, subjects had tobebetween5 and 14 years of age
with a DSM-IV diagnosis of autistic disorder, Asperger’s
syndrome, or pervasive developmental disorder not other-
wise speciﬁed, basedonclinical assessment andcorroborated
by the Autism Diagnostic Observation Schedule (18) and the
Social Communication Questionnaire (19). The Autism Di-
agnostic Observation Schedule is a clinician-administered
procedure that places the child in naturalistic social situations
designed to elicit social and communication responses. The
Social Communication Questionnaire is a 40-item parent-
completed survey that evaluates the child’s communication
and social functioning. The lifetime version of the question-
naire provides a total score that can be compared against
normative data as further support for an ASD diagnosis. The
pretreatment assessment also included routine laboratory
tests (blood counts, electrolytes, liver function tests, blood
urea nitrogen, creatinine, and urinalysis), medical and psy-
chiatric histories, a physical examination, and vital sign eval-
uation. The screening and week-8 ECG were reviewed by
a pediatric cardiologist at each site.
The primary targets of the treatment were hyperactivity,
impulsiveness, and distractibility. Therefore,we set aminimum
score of 24 on the parent-rated Aberrant Behavior Checklist-
hyperactivity subscale for study eligibility (see below). In
addition, a Clinical Global Impression-Severity (CGI-S) score
of moderate or greater was required for entry. The CGI is a
7-itemscale,whichranges from1 (normal) through4 (moderate)
to 7 (extreme), designed to rate overall symptomseverity (17).
In addition to hyperactivity, impulsiveness, and distractibility,
raters considered all aspects of the child’s clinical picture to
assign the CGI-S score.
Based on the Abbreviated Stanford-Binet Intelligence
Scales (20) or the Mullen Scales of Early Learning (21),
subjects had to have an IQ of 35 (or mental age of 18 months)
or greater. Anticonvulsant medication for seizures was
allowed if the dose was stable (at least 4 weeks) and the
subject was seizure-free for at least 6 months. Otherwise,
subjects had to bemedication-free prior to baseline. Subjects
taking a psychotropic treatment deemed ineffective were
required to be withdrawn from the medication for at least 1
week for stimulants or clonidine, 2 weeks for atomoxetine
andmost antidepressants, and3weeks forﬂuoxetine, citalopram,
and antipsychotics. Children with a signiﬁcant medical con-
dition by history, physical examination, or laboratory testing
were excluded. Girls with a positive pregnancy test were also
excluded.
To screen for other DSM-IV disorders, we relied on
clinical evaluation supplemented by the parent-completed
Child andAdolescentSymptomInventory (22).This 132-item
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DSM-IV-based checklist asksparents to rate symptoms in the
major psychiatric disorders of childhood on a 4-point scale
(0=never; 1=sometimes; 2=often; and 3=very often). Scores of
2 or 3 are regarded as a positive symptom for the given
disorder. Children with a lifetime diagnosis of psychosis or
bipolar disorder or current diagnosis of major depression,
obsessive-compulsive disorder, or substance abuse were
excluded. To assess adaptive functioning at baseline, we used
the parent-rated Vineland Adaptive Behavior Scales II
(Vineland II) (23). The Vineland II provides standard scores
in three domains: communication, socialization, and daily
living skills. Prior to administration, parents were instructed
to consider adaptive skills that the child is unable to perform
(score of 0); skills that the child performs sometimes (score of
1); and skills that the child regularly performs (score of 2).
Outcome Measures
The primary outcome measure was the parent-rated Aber-
rant Behavior Checklist-hyperactivity subscale (9, 24, 25).
The full Aberrant Behavior Checklist is a 58-item parent
rating with ﬁve factors: irritability, social withdrawal, ste-
reotypy,hyperactivity, and inappropriate speech.The16-item
hyperactivity subscale (collected at baseline, weeks 4, 6, and
8) covers over-activity (seven items), impulsiveness (two
items), inattention (three items), and noncompliance (four
items). It has been used as a primary outcome measure in sev-
eral trials of children with developmental disabilities (12, 16).
Two blinded clinicians followed each subject: a treating
clinician andan independent evaluator.The treating clinician
adjusted the dose of the medication and monitored adverse
events. The independent evaluator assessed key secondary
outcomes, including scores for the improvement item of the
CGI (17) and the ADHD Rating Scale (26). To protect the
blind, the independent evaluator did not discuss adverse
effects or dosing. The ADHD Rating Scale is an 18-item scale
directly derived from DSM-IV criteria for ADHD with
established reliability, validity, and sensitivity to change
(26–28). The CGI-I is a 7-point scale designed to measure
overall symptomatic change compared with baseline. Scores
range from1 (verymuch improved) through4 (unchanged) to
7 (verymuchworse).A ratingofmuch improvedorverymuch
improved on the CGI-I at week 8 was used to deﬁne positive
response. As noted, the treatment mask was broken for
subjects who did not showa positive response. The blindwas
broken by the treating clinician, and treatment statuswas not
disclosed to independent evaluators.
Experienced investigators (L.S., B.K.) trained study in-
dependent evaluatorson theCGI (severityand improvement)
using case vignettes for illustration and discussion. To be
considered reliable, raters had to be in full agreement on the
CGI (severity and improvement)with thegold standard score
on at least one vignette. In addition, independent evaluators
had to be within one unit of the gold standard without dis-
agreement on study eligibility or treatment response on two
other vignettes. For example, if the gold standard baseline
CGI-Swasmoderate (4) and thenewratergavea scoreofmild
(3), this one unit difference would affect eligibility and was
considered unreliable. Similarly, on the CGI-I, if the gold
standardscorewas2 (much improved)and thenewratergave
a score of 3 (minimally improved), this was unacceptable
because of the disagreement on classiﬁcation. Independent
evaluators also received training on the administration of the
ADHD Rating Scale and had to be within 4 points on two
video recordings compared with the expert rater. In-
dependent evaluators participated in monthly conference
calls to review cases and to promote a common approach to
conducting assessments across sites.
Four cognitive tests were administered at baseline and
week 8 by psychologists whowere trained to reliability and
blind to treatment assignment. The tests included the
Recognition of Pictures and Digit Recall subtests from the
Differential Ability Scales II (29) and the Imitating Hand
Positions and Manual Motor Sequences from the sensori-
motor domain of the NEPSY II (30). To assess working
memory, the Recognition of Pictures presents pictures of
objects for 5–10 seconds to the child. The examiner then
presents a new page with the same objects mixed with
distracter pictures and asks the child to point to the original
objects. The Recall of Digits is also a working memory task
in which the child is asked to repeat a sequence of digits
presented orally by the examiner. Sequences start with two
digits and increase progressively up to nine digits or until
the child meets the discontinuation rule. The Imitating
Hand Positions test assesses motor planning by asking the
child to imitate the examiner’s hand and ﬁnger positions
with the dominant hand, nondominant hand, and both
hands. The Manual Motor Sequences task measures the
ability of the child to imitate a series of rhythmic move-
ments by the examiner using one or both hands.
Medication Schedule
The extended-release guanfacine formulation is undermined
if the tablets are crushed or broken. Thus, we conﬁrmed that
each subjectwas able to swallow thewhole tablet. The starting
morning dose for all children was 1 mg per day. Children
weighing less than 25 kg remained on the 1-mg dose until
day 14. If the medication was well-tolerated, the dose could
be raised to 2 mg until day 28 and increased to 3 mg for the
remaining 4 weeks in the trial. Children weighing 25 kg or
morewere eligible for an increase to 2mg at day 7, 3mg at day
14, and 4 mg at day 21 or day 28. The dose schedule was not
ﬁxed; the treating clinician could delay a planned increase
or lower the dose to manage adverse effects. The treating
clinician could also switch to an evening dose to manage
daytime drowsiness.
Safety Monitoring
Subjects were seen weekly for the ﬁrst 4 weeks, then at
weeks 6 and 8. Blood pressure and pulse sitting at rest and
height and weight were measured at each visit. Routine
laboratory tests were not repeated at week 8 in the absence
of evidence that guanfacine affects these indices (31, 32). An
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ECGwas obtained atweek 8 (or early termination) to assess
the impact of guanfacine on cardiac conduction.
Adverse events were also systematically reviewed and
documented at each visit. At baseline, the treating clinician
conducted the 34-item Pretreatment Health and Behavior
Review, developed by the Research Units on Pediatric
Psychopharmacology Autism Network (4, 12), to collect pre-
treatment data on mild, moderate, or severe health com-
plaints, as well as activity level, appetite, bowel function,
sleep, and dermatological problems. Following a similar
format, the treating clinician reviewed the 34-item Adverse
Event Review to identify new adverse effects after random
assignment. New adverse events, whether presumed related
to treatment or not, were rated as mild (no impairment),
moderate (some impairment or need for intervention to
prevent impairment), severe (evidence of impairment and
need for intervention), serious (need for hospitalization or
major threat tohealth andwell-being).Adecreaseof 10mmof
Hg in diastolic blood pressure or a shift into the abnormal
range (i.e.,.2standarddeviationsbelowthenormal range for
age and gender) was documented as an adverse event. For
these subjects, blood pressure was repeated after a 5- to 10-
minute resting period. If the 10-mm drop in the diastolic
blood pressure persisted on repeat measurement during the
same visit, the dose was reduced.
Analytic Plan
The population mean score on the Aberrant Behavior
Checklist-hyperactivity subscale for developmentally dis-
abled boys in this age group was 13 (SD=11.3) (slightly lower
for girls). Study eligibility required a medication-free Aber-
rant Behavior Checklist-hyperactivity subscale score .24.
To estimate sample size, we predicted a mean hyperactivity
subscale score at baseline of 30 (SD=10) (approximately 1.5
standard deviations above the population mean). Based on
previous studies, we predicted incremental, linear im-
provement for extended-release guanfacine over time. We
estimated the power to detect a clinically meaningful effect
size of 0.55 across a range of sample sizes in a series of
simulations using a random regression model. To estimate
the correlation of repeated parent-rated Aberrant Behavior
Checklist-hyperactivity subscale scores, we used data from
subjects randomly assigned to placebo in our previous trial
comparing risperidone with placebo (4). The correlations
ranged from 0.63–0.85 over that 8-week trial. For the linear
trend hypothesis, a sample size of 60 provided 85.5% power
assuming a test-retest correlation of 0.7 on the Aberrant
Behavior Checklist-hyperactivity subscale. Power would be
slightly reduced if the correlationwere 0.63 and greater if the
correlation were 0.8.
All randomly assigned subjects were included in the
intent-to-treat analyses. Preliminary analyses included
descriptive statistics for baseline measures in each treat-
ment group, as well as examination of scores within each
group at weeks 4 and 8. To evaluate the effect of treatment
over time, we used a mixed-effect linear model on the
primary outcome measure (parent-rated Aberrant Behavior
Checklist-hyperactivity subscale). Study group and site
were the ﬁxed effects; time and outcome were the random
effects (33). Using the baseline Aberrant Behavior Checklist-
hyperactivity subscale score as a ﬁxed effect in the model,
each subject’s response was modeled by regressing the
score against time.The intercept and slope of the regression
were allowed to vary randomly between subjects. A linear
contrast of group differences at 8 weeks (i.e., clinical re-
sponse) was performed and tested for statistical signiﬁ-
cance. We used a similar approach for the key secondary
outcome, the ADHD Rating Scale score collected at base-
line, week 4, and week 8. To evaluate overall improvement,
we compared the proportion of subjects rated as much
improved or very much improved on the CGI-I by the
independent evaluator in each treatment group using chi-
square analysis.
All analyses were conducted using SAS/STAT software,
version 9.3. In addition, p values #0.05 were accepted as
statistically signiﬁcant for the Aberrant Behavior Checklist-
hyperactivity subscale, the ADHD Rating Scale, and the
CGI-I,withBonferroni correction for otherAberrantBehavior
Checklist subscales. The analysis proceeded on the assumption
thatmissing dataweremissing at random. Although there is no
proven method for verifying this assumption, we compared
selected demographic and clinical characteristics of subjects
who dropped out with these characteristics in the remaining
sample (34). The rate of adverse effects greater than 5% was
compared across treatment groups by chi-square analysis;
p values #0.10 were considered statistically signiﬁcant for
adverse events.
FIGURE 1. CONSORT Diagram of Study Flow
Placebo (N=32) ER-guanfacine (N=30)
Discontinued early (N=4) 
due to lack of effi  cacy
Discontinued early (N=4*) due to 
adverse events (N=2), 
lack of effi  cacy/study burden 
(N=2)
Completed (N=28)
Analyzed (N=32)
Completed (N=26)
Analyzed (N=30)
Screened (N=81)
Randomized (N=62)
Ineligible (N=13) 
Declined (N=6)
* Two additional subjects discontinued treatment because of adverse
events but remained in the study.
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RESULTS
Eighty-one children were screened; 62 (boys,
N=53; girls, N=9) eligible subjects were ran-
domly assigned to extended-release guanfacine
(N=30) or placebo (N=32) (Figure 1). Subjects
ranged in age from 5 to 14 years (mean=8.5
years [SD=2.25]). There were no differences
in demographic and clinical characteristics
between treatment groups (see Table 1). Eight
subjects (12.9%) dropped out before week 8
(four from each group). The demographic and
baseline clinical characteristics for these eight
subjects were not different than these char-
acteristics for the 54 subjects who completed
the trial. Thirty-four subjects (54.8%) were
drug naive. Twenty-six children (41.9%) were
medication-free at screening but had been
treated with various medications in the past.
In collaboration with the child’s primary clini-
cian, parents decided to discontinue a current
medication for two subjects (3.2%). One subject
entered following a 3-week washout of ﬂu-
oxetine, and one entered following a 4-week
washout of aripiprazole.
Table 2 shows that guanfacine was supe-
rior to placebo on the parent-rated Aberrant
Behavior Checklist-hyperactivity subscale
(p,0.001, effect size=1.67) and the clinician-
rated ADHD Rating Scale (p,0.001 for all
three measures). The change in the least-
squares means on the Aberrant Behavior
Checklist-hyperactivity subscale over the
8-week trial is presented in Figure 2. The
guanfacine group showed a 43.6% decline in
the Aberrant Behavior Checklist-hyperactivity
subscale score (least-squares mean values
were 34.2 at baseline to 19.3 at week 8)
compared with a 13.2% decrease for placebo
(34.2 at baseline to 29.7 at week 8, p,0.001).
The rate of positive response (much improved
or very much improved on the CGI-I) was
50% (N=15/30) for guanfacine comparedwith
9.4% (N=3/32) for placebo (p=0.0001; num-
ber needed to treat=2). Baseline and week
8 scores on all Aberrant Behavior Checklist
subscales are presented in Table 2. The
extended-release guanfacine group showed
modest beneﬁt on the Aberrant Behavior
Checklist-stereotypy and inappropriate speech
subscales (the latter remained signiﬁcant after
Bonferroni correction).
Cognitive Testing
Fifty-nine of 62 subjects had some cognitive testing results.
Among those 59, complete data were available for 51 children,
with no difference in missing data across treatment groups.
Performance scores at baseline andweek 8 on the 17 subtests
TABLE 1. Baseline Characteristics of Children Randomly Assigned to Extended-
Release Guanfacine or Placebo
Characteristic
Guanfacine
(N=30)
Placebo
(N=32) p
N % N %
Male 26 86.67 27 84.38 0.99
DSM-IV diagnosis 0.31
Autistic disorder 25 83.33 26 81.25
Pervasive developmental disorder not
otherwise speciﬁed
3 10.00 6 18.75
Asperger’s syndrome 2 6.67 0 0.00
IQa
,70 19 63.33 20 62.50
$70 11 36.67 10 31.25
Clinical Global Impression-Severity 0.79b
Moderately ill 12 40.00 12 37.50
Markedly ill 17 56.67 17 53.13
Severely ill 1 3.33 3 9.38
Tanner stage 0.99
1 or 2 29 96.67 31 96.87
3 1 3.33 1 3.13
Race/ethnicityc 0.34
White 17 56.67 23 68.75
Black 7 23.3 4 12.50
Asian 4 13.33 1 3.13
Paciﬁc Islander 1 3.33 1 3.13
Mixed 1 3.33 3 9.38
Maternal education 0.21
Less than high school 1 3.33 0 0.00
High school graduate or GED 4 13.33 3 9.38
Some college or post-high school or
2-year degree
4 16.67 12 34.37
4-year college graduate 15 56.67 12 31.25
Graduate or professional school 6 20.0 5 15.62
School Placement 0.30
Regular class public or private school 16 53.3 21 65.62
Special education program 14 46.7 10 31.25
Home school 0 0.00 1 3.13
Mean SD Mean SD
Social Communication Questionnaire
score
23.86 6.43 21.42 6.40 0.15
Vineland Adaptive Behavior Scales II
score
Socialization 66.80 14.35 67.12 14.88 0.93
Communication 72.92 20.07 73.50 13.66 0.40
Daily living 72.69 19.92 74.15 15.88 0.77
Aberrant Behavior Checklist
Irritability 20.30 9.4 18.06 9.77 0.3623
Social withdrawal 13.60 9.43 12.06 9.29 0.5204
Stereotypy 8.53 5.69 9.31 5.56 0.5873
Hyperactivity 34.40 5.35 34.25 6.97 0.9250
Inappropriate speech 6.33 3.53 6.84 3.38 0.5628
ADHD Rating Scale
Inattention 20.53 3.66 20.41 4.59 0.9048
Hyperactivity/impulsiveness 19.00 4.35 19.50 4.95 0.6750
Total 39.53 5.89 39.91 6.68 0.8169
a Data are missing for two subjects in the placebo group.
b The p value represents the proportion of subjects .moderate on Clinical Global Impression-
Severity by group.
c There were two Hispanic subjects in the active treatment arm and four in the placebo group.
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analyzed are presented in Table 3. There were no group
differences at baseline, and analysis of covariance models
(adjusted for IQ$70 and,70) showed no group differences
from baseline to endpoint on any subtests. The interactions
between cognitive test scores at baseline and treatment were
not signiﬁcant. Examination onwhether performance on any
cognitive subtest predicted positive outcome in either
treatment group was uninformative.
Medication Dose
The modal daily dose at week 8 was 3 mg/day (range:
1 mg/day–4 mg/day) for the extended-release guanfacine
group and 3 mg/day (range: 2 mg/day–4 mg/day) for the
placebo group.
Safety Results
The numbers and percentages of subjects with parent-
reported mild, moderate, and severe adverse events are
shown in Table 4. The adverse event labels in this table were
derived from a list of preferred terms established before
launching the study. The items on the Adverse Event Review
and verbatim complaints were matched to the preferred
terms. Therewas one serious adverse event in the guanfacine
treatment group.Sixdays after the scheduled increase to2mg
per day, the child (a 6 year-9-month-old boy) became verbally
andphysically aggressive towardhismother. The policewere
summoned, and the boy was taken to the emergency room.
Upon evaluation, he was agitated and threatened hospital
personnel, and his speech was pressured. The medication
was discontinued, and he remained on the child psychiatric
inpatient service for 3 days. Upon discharge, he was hyper-
active and impulsive (similar to baseline).Hewasnot agitated
or aggressive, and his speech was normal in tone and tempo.
During the entire episode, there was no change in his sleep.
The study medication was discontinued for this subject, but
assessments were continued. One other subject in the
guanfacine group also stopped treatmentwith the study drug
because of adverse events and remained in the study for
assessment. As shown in Figure 1, two subjects in the
guanfacine group dropped out of the study completely be-
cause of multiple adverse events (drowsiness, fatigue, mid-sleep
TABLE 2. Scores on the Aberrant Behavior Checklist and ADHD Rating Scale at Baseline and Endpoint (Week 8)
Measure
Guanfacine (N=30) Placebo (N=32)
p
Effect
Sizeb
Raw Mean Least-Squares Meana Raw Mean Least-Squares Meana
Baseline 95% CI Endpoint 95% CI Baseline 95% CI Endpoint 95% CI
Aberrant
Behavior
Checklist
Subscale
Hyperactivityc 34.40 32.40–36.40 19.3 15.33–23.22 34.25 31.74–36.76 29.7 25.82–33.53 ,0.0001 1.67
Irritability 20.30 16.79–23.81 13.5 10.01–17.06 18.06 14.54–21.58 16.1 12.68–19.54 0.20 0.27
Social
withdrawal
13.60 10.08–17.12 9.8 7.26–12.27 12.06 8.71–15.41 8.6 6.10–11.02 0.41 0.13
Stereotypy 8.53 6.41–10.66 3.6 2.03–5.26 9.31 7.31–11.32 5.9 4.37–7.49 0.02 0.41
Inappropriate
speech
6.33 5.02–7.65 4.2 3.24–5.26 6.84 5.63–8.06 5.99 4.50–6.97 0.004 0.50
ADHD Rating
Scale
Inattention 20.53 19.17–21.90 14.7 12.55–16.78 20.41 18.75–22.06 19.5 17.52–21.56 0.0001 1.17
Hyperactivity 19.00 17.38–20.62 10.6 8.50–12.75 19.50 17.71–21.29 18.7 16.6–20.69 ,0.0001 1.72
Total 39.53 37.33–41.73 25.2 21.44–29.03 39.91 37.50–42.32 38.0 34.4–41.63 ,0.0001 2.03
a Atweek 8, the least-squaresmean values on the hyperactivity subscalewerewithin 1 standard deviation of the populationmean; the least-squaresmean values at
endpoint are adjusted for baseline.
b Effect sizes were calculated by taking the difference in the least-squares means at endpoint and dividing by the pooled standard deviation at baseline.
c Rawbaseline scores on theAberrant BehaviorChecklist-hyperactivity subscalewere nearly 2 standard deviations above thepopulationmean for developmentally
disabled children 6 to 10 years of age.
FIGURE 2. Least-Squares Means on Aberrant Behavior Checklist-
Hyperactivity Subscale Scores for Extended-Release Guanfacine
and Placebo During the 8-Week Triala
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awakening, and emotional lability), and two dropped out
because of lack of efﬁcacy.
Nine subjects on active medication had a dose reduction
because of suspected treatment-related adverse events
(e.g., drowsiness, emotional/tearful presentation, irritability,
and/or lowered blood pressure). Five placebo-treated sub-
jects had dose adjustments in response to similar complaints.
The term irritability reﬂects the combination of anger out-
bursts and low frustration tolerance, with disruptive behavior.
By contrast, emotional/tearful captures what parents called
“emotionally fragile” or “tearful and cranky.” Although less
common, sleep disturbance (trouble falling asleep or mid-
sleep awakening) also prompted dose reduction.
ECGdatacollectedat screeningandweek8werereviewed
by a board-certiﬁed pediatric cardiologist at each site. Mild,
not clinically signiﬁcant, ECGabnormalitiesweredetected in
12 subjects at baseline and eight subjects at week 8 (active
treatment, N=5; placebo, N=3). In guanfacine-treated sub-
jects, sinus bradycardia was the most commonly reported
ﬁnding. One subject had a borderline QTc prolongation of
461 ms at screening that was considered not clinically sig-
niﬁcant. At week 8, this subject had a QTc of 465, also
considered not clinically signiﬁcant. No subject had a QRS
interval greater than 120 ms, and no other subject had a QTc
greater than 450ms. Systolic and diastolic blood pressure, as
well as pulse, for 53 subjects with complete data across the 8-
week trial are shown in Figure 3A, Figure 3B, and Figure 3C.
Sixteen subjects had a $10-point drop in diastolic blood
pressure in the guanfacine group compared with nine in the
placebo group (p=0.04).
DISCUSSION
Extended-release guanfacine is approved by the U.S. Food and
Drug Administration for the treatment of children with ADHD
(28, 30). The results of this trial indicate that extended-release
guanfacine is safe and effective for short-term treatment of
hyperactivity, impulsiveness, and distractibility in childrenwith
ASD. The rate of positive response on the CGI-I is similar to
what has been reported in previous trials of extended-release
guanfacine in children with ADHD (28, 30). The results of the
present study extend pilot study ﬁndings of immediate-release
guanfacine in this population (16, 35). The primary outcome
measure (Aberrant Behavior Checklist-hyperactivity subscale)
includes items on hyperactivity, impulsiveness, inattention, and
noncompliance that do notmapdirectly on anADHDdiagnosis.
On theDSM-IV-referencedADHDRatingScale (a key secondary
measure), however, we also observed signiﬁcant effects on
hyperactivity, impulsiveness, and inattention.
The 43.6% decline in scores (effect size=1.67) on the
parent-rated Aberrant Behavior Checklist-hyperactivity sub-
scale from baseline to week 8 in this trial is greater than
the 31%–38% reduction (effect sizes ranged from 0.29 to
0.54) across the threeﬁxed-dose levels ofmethylphenidate in
TABLE 3. Scores on the Subtests of the Differential Ability Scales II and NEPSY II at Baseline and Endpoint (Week 8)
Cognitive Task
Guanfacinea Placebob
pc
Baseline Week 8 Baseline Week 8
Mean SD Mean SD Mean SD Mean SD
Differential Ability Scales Picture
Recognition
Raw score 5.59 3.45 5.65 4.02 6.67 4.77 6.86 4.38 0.79
Ability score 86.24 40.24 88.04 44.07 88.57 47.23 94.64 44.85 0.86
T-Score 34.45 14.51 34.77 16.18 37.57 21.51 39.29 20.87 0.94
Differential Ability Scales Recall of
Digits
Longest string correct 4.65 1.20 4.39 1.31 4.70 1.68 4.61 1.55 0.91
Raw score 12.81 6.23 12.04 7.03 14.07 7.55 13.90 7.61 0.81
Ability score 107.68 43.38 102.44 50.20 112.83 53.33 114.72 51.19 0.58
T-Score 33.21 14.22 32.36 16.80 36.27 17.63 35.62 17.83 0.41
NEPSY Hand Positions
Dominant hand 1.83 0.38 1.88 0.33 1.97 0.18 1.93 0.26 0.31
Dominant hand raw score 6.17 3.27 6.65 3.42 5.40 3.59 6.69 3.72 0.32
Nondominant hand 1.21 0.41 1.12 0.33 1.07 0.25 1.07 0.26 0.62
Nondominant hand raw score 6.41 3.46 6.73 3.66 5.10 4.41 5.79 3.77 0.72
Total raw score 12.59 6.41 13.38 6.70 10.50 7.61 12.48 7.30 0.49
Total scaled score 5.00 2.55 5.36 2.41 4.46 3.16 5.64 3.72 0.47
NEPSY Manual Motor Sequences
Highest item score 7.10 3.43 8.13 3.07 7.59 3.83 7.59 3.78 0.37
Total raw score 24.39 14.28 27.08 15.36 27.07 15.63 28.83 17.79 0.90
Percentile rank 2.00 1.04 2.15 1.05 2.32 1.12 2.50 1.23 0.61
Rate change 4.08 3.96 2.64 2.87 2.96 2.77 3.86 3.57 0.18
a Sample sizes range from 25 to 29.
b Sample sizes range from 27 to 30 due to missing data.
c Data represent p values from the analysis of covariance models (adjusted for IQ $70 or ,70)
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the crossover trial (12). However, on the predetermined al-
gorithm used to deﬁne the optimal dose of methylphenidate,
therewas a 48%reduction (effect size=0.89) frombaseline on
the parent-rated Aberrant Behavior Checklist-hyperactivity
subscale. The smaller effect size for the optimal dose in the
methylphenidate study is due inpart to the 22%decline in the
placebo group in theprior study comparedwith a 13%decline
in the guanfacine trial. Treatment for four of 30 guanfacine-
treated subjects (13.3%) in the present study was dis-
continued because of adverse events (two remained in the
study; two exited the study). By contrast, 18% (13 of 72)
subjectsdiscontinued themethylphenidate trial.On theCGI-I,
the 50% positive response rate for guanfacine was nearly
identical to the rate observed in the methylphenidate trial.
Although it is difﬁcult to compare the results of this 8-week
parallel trial to the 4-week ﬁxed-dose methylphenidate
crossover trial, the magnitude of effect and tolerability
appears slightly better for extended-release guanfacine for
reducing ADHD symptoms in children with ASD. There are
no identiﬁed predictors of positive response to either drug.
Both drugs require careful monitoring to balance tolerability
and beneﬁts.
In the total score of the clinician-administered ADHD
Rating Scale, we observed a 34% improvement from baseline
toweek8 anda50%positive response rate on theCGI-I. In an
8-week double-blind placebo-controlled trial of atomoxetine
in 97 childrenwith ASD and ADHD symptoms, Harfterkamp
et al. (15) reported a 22% improvement on the ADHD Rating
Scale and a 21% positive response rate on the CGI-I. These
TABLE 4. Adverse Events by Treatment Group Reported in >5%of
Study Subjects
Adverse Event
Guanfacine Placebo
pN % N %
Drowsiness 26 86.7 3 9.4 ,0.001
Fatigue 19 63.3 3 9.4 ,0.001
Decreased appetite 13 43.3 2 6.25 ,0.001
Emotional/tearful 12 40 3 9.4 0.01
Dry mouth 12 40 1 3.1 ,0.001
Irritability 11 36.7 3 9.4 0.01
Anxiety 9 30 1 3.13 0.01
Headache 9 30 6 18.75 0.30
Increased energy 9 30 6 18.75 0.30
Mid-sleep awakening 9 30 2 6.25 0.02
Stomachache 8 26.7 4 12.5 0.21
Constipation 7 23.3 2 6.25 0.08
Increased repetitive behavior 5 16.7 3 9.4 0.47
Aggression 5 16.7 2 6.25 0.25
Depressed mood 4 13.3 1 3.1 0.19
Cough/congestion 4 13.3 4 12.5 0.99
Self-injury 3 10 0 0 0.11
Nausea 3 10 2 6.25 0.67
Trouble falling asleep 3 10 2 6.25 0.67
Dizziness 3 10 2 6.25 0.67
Silly 3 10 5 15.6 0.71
Weakness 3 10 1 3.1 0.35
Diarrhea 3 10 0 0 0.11
Vomiting 3 6.7 3 9.4 0.99
Increased appetite 2 6.7 2 6.25 0.99
Excessive talking 2 6.7 9 28.1 0.04
Blurred vision 2 6.7 0 0 0.23
Skin rash/eczema 2 6.7 4 12.5 0.67
Nightmares 2 6.7 0 0 0.23
Enuresis 2 6.7 2 6.25 0.99
Motor tics 1 3.3 2 6.25 0.99
Skin picking 1 3.3 3 9.4 0.61
Fever 1 3.4 3 9.4 0.61
FIGURE 3. MeanChange FromBaseline of Systolic Blood Pressure,
Diastolic Blood Pressure, and Pulse Rate for Subjects With
Complete Data by Treatment Condition
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contrasting results support the selection of extended-release
guanfacine over atomoxetine in this clinical population.
The most common adverse events leading to dose re-
duction with extended-release guanfacine were drowsiness,
fatigue, emotional fragility, tearfulness, and irritability. In a
5-week ﬁxed-dose trial (placebo 2, 3, or 4 mg/day) of
extended-release guanfacine, Biederman et al. (28) reported
a similar pattern of adverse effects but at lower rates. Simi-
larly, systolic anddiastolic bloodpressures andpulsedeclined
during the dose escalation phase in the present study, which
is consistent with ﬁndings in studies of extended-release
guanfacine in children with ADHD (28). Blood pressure
readings returnednearly tobaselinemeasurementsbyweek8
in the present study. Heart rate remained about 10 points
below baseline at week 8 in the guanfacine-treated group.
Therewere no clinically signiﬁcant changes frombaseline on
the ECG. These results suggest that monitoring blood pres-
sure and pulse is warranted, especially early in treatment.
The alpha2 agonists guanfacine and clonidine were de-
veloped as antihypertensives. The stimulation of presynaptic
alpha2 receptors reduces tonic ﬁring of locus coeruleus
neurons, resulting in slower heart rate and decreased blood
pressure (36). A rich body of preclinical evidence indicates
that norepinephrine neurons in the locus coeruleus also
regulate arousal and play an essential role in interpretation of
sensory stimuli and behavioral response (37). These multiple
functions are managed by the balance of tonic and phasic
ﬁring of locus coeruleus neurons in concert with reciprocal
cortical connections. Accumulated evidence over the past 25
years also demonstrates that guanfacine stimulates alpha2A
receptors in the prefrontal cortex, with potential beneﬁts in
working memory, attention, and impulse control (38). In the
present study, we did not detect differences between guan-
facine and placebo on tests of working memory or motor
planning. It appears that guanfacine did not enhance or
hinder cognitive functioning in this sample. Both mecha-
nisms (reduced tonic ﬁring of locus coeruleus neurons and
stimulation of prefrontal alpha2A receptors) may have con-
tributed to the clinical results of this study.
Although symptoms of ADHD and ASD often co-occur and
may reﬂect shared underlying genetic risk (39, 40), the ADHD
syndrome in ASD may differ from ADHD in children without
ASD. Children with ASDmay be internally focused on topics of
special interest, ﬁnd little reward in matters outside of their
circumscribed interest, and, consequently, pay little attention to
otherenvironmental stimuli.Hyperactivityand impulsiveness in
children with ASD appear similar to the hyperactivity and im-
pulsiveness in ADHD and are more amenable to measurement.
The signiﬁcant improvement in ADHD symptoms in the
guanfacine-treated group compared with placebo notwith-
standing, the trial has several limitations. This study provides
only acute efﬁcacy and safety results. Furthermore, wide
variability in school settings and enrollment during summer
months precluded collection of teacher ratings. Finally, the
sample size limits the ability to identify clinical character-
istics that moderate treatment response.
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